Publications

Publications & scientific presentations

GlycoNex's work is grounded in more than two decades of glycobiology research. Below is a selection of peer-reviewed publications and scientific conference presentations across the company's glycan-directed antibody and ADC programs. A complete bibliography is being compiled.

01 — Peer-reviewed publications

Peer-reviewed publications

—
Journal article

Preclinical validation of a pro-antibody antibody-drug conjugate built on antibody-lock technology

International Journal of Biological Macromolecules (Impact Factor 8.5). Preclinical study underpinning GlycoNex's pro-antibody ADC program (GNX201-ADC).

This page lists a selection of GlycoNex's scientific output and is being expanded. For specific publications, reprints, or scientific inquiries, please contact mail@glyconex.com.tw.
02 — Conference presentations

Conference presentations

2026
Oral presentation

Glycan-directed antibody and ADC development

SialoGlyco 2026 — oral presentation.

2025
Poster

Preclinical data on GNX1021, a glycan-targeted ADC for gastrointestinal cancers

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025.

2025
Poster

Preclinical characterization of GNX1021 targeting branched Lewis B/Y

AACR Annual Meeting 2025.

2025
Corporate presentation

GlycoNex corporate and pipeline overview

Biotech Showcase 2025, during J.P. Morgan Healthcare Conference week.

Looking for the science behind the pipeline?

For reprints, preprints, or scientific collaboration inquiries, our team is happy to help.

Contact us →
Continue exploring
Technology The GlycoSH anti-glycan antibody collection, glycan-directed ADC programs, and the GlycoBind detection platform behind GlycoNex's science. Explore technology → Pipeline Clinical and preclinical programs across glycan-directed ADCs and biosimilars. View pipeline → News Recent milestones, partnerships, and regulatory updates from GlycoNex. View news →